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Abstract Hemicrania continua (HC) is a rare primary
headache syndrome, characterized by unilateral pain and
an absolute response to indometacin. Since the term was
first coined in 1984, more than 100 cases have been
described worldwide. Most recently, detailed case series
that provide more detailed information concerning the
sometimes complex clinical presentation of HC have been
reported. Functional imaging studies suggest a unique
pattern of subcortical involvement in HC: contralateral to
the pain posterior hypothalamic region, ipsilateral dorsal
pons and ipsilateral ventral midbrain, which, along with the
particular effect of indometacin, probably justifies its
classification as a unique entity. Increasing the awareness
of this primary headache form among clinicians will aid in
its diagnosis while further work is being undertaken to
characterize the syndrome.
Keywords Chronic daily headache.Indometacin-sensitive
headache.Indometacin test.Trigeminal autonomic
cephalalgias.International classification of headache
disorders
Introduction
The first description of the syndrome was probably as a
cluster headache variant with strictly unilateral, continuous
headache responding to indometacin [1]. Subsequently, the
disorder was named hemicrania continua (HC) [2]: the
index patients were a woman (age 63 years) and a man (age
53 years) who developed a strictly unilateral continuous
pain from onset and were completely responsive to
indometacin. Interestingly, 1 year earlier, a 49-year-old
man who had a history of more than 20 years of unilateral
pain, mainly localized on the left side, and also had a
dramatic response to indometacin was described [3].
Case Series
Following the description by Sjaastad and Spierings [2],
more than 100 cases of HC have been described. The first
case series was reported in 1991 with 18 cases reviewed
from the literature [4]. Newman and colleagues [5]
described 10 new cases and reviewed 24 cases from the
literature in an attempt to better describe the clinical picture
and temporal profile. In 1999, Espada and colleagues [6]
described the long-term outcome of the indometacin
response in five men and four women. Peres and colleagues
[7] described 34 new cases to highlight this syndrome, and
Pareja and colleagues [8] reviewed 16 patients with HC to
assess doses and the side effects of prolonged indometacin
treatment. Bigal and colleagues [9] retrospectively de-
scribed 10 cases, and Wheeler [10] described six cases of
HC in African-Americans. Klein and colleagues [11]
retrospectively described eight patients with HC that had
neuro-ophthalmologic presentations. In 2009, Marmura and
colleagues [12￿] retrospectively reviewed the clinical charts
of 43 patients with positive response to indometacin versus
122 patients with a negative response to indometacin to
identify possible clinical differences, which is in practice a
very substantial issue. The authors compared the two
groups for age, sex, presence or absence of specific
autonomic symptoms, medication overuse, rapid onset of
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Society (IHS) criteria for migraine when severe. The study
did not show any difference in the demographics or clinical
characteristics of these two groups, supporting the clinical
impression that it is challenging to identify clinical
characteristics that can predict a response to indometacin.
In the study, the frequent diagnosis of patients who did not
respond to indometacin included chronic migraine with and
without medication overuse, new daily–persistent headache
(NDPH), nummular headache, or cervicogenic headache
[13]. Further, 24 of 42 patients (57%) had cranial
autonomic features required by the International Classifi-
cation of Headache Disorders (ICHD) [14] and 55% of the
patients exhibited medication overuse. In a previous study
[7], 25 of 34 patients (73.5%) had at least one cranial
autonomic feature according to the Goadsby and Lipton
criteria [15], and in the most recent study [16￿￿], 37 of 39
patients (95%) with HC had at least one cranial autonomic
feature. However, some of the features in the cohort are not
in the current diagnostic criteria, including forehead/facial
flushing, itching of the eye, eyelid edema, and a sense of
aural fullness or swelling. In addition, 3 of 39 patients had
side-shifting pain, and there are reports of patients with
side-shifting pain in the literature [16￿￿]. Overall, it
emerged that some of the current criteria for HC [14] are
restrictive and that there is a need for the revision of the
current criteria.
Epidemiology and Sex Distribution
The incidence and prevalence of HC is unknown.
Initially, it was considered to be a very rare syndrome.
However, the increasing number of patients identified in
headache subspecialty clinics has led some to suggest
the condition may be underdiagnosed [7, 17]. On the
other hand, the diagnosis of a relatively small group of
patients with HC over a period of 13 years [16￿￿]i na
tertiary center, using strict indometacin-response criteria,
suggests the condition is rare. Only a large population-
based study will properly provide clear information about
the prevalence of this condition. In the latest study of 39
patients with HC [16￿￿], the range of headache onset was
between 10 and 67 years, and this data confirms the
existing literature that states this condition can begin at
any age; the mean age at onset is in the 30 s. In the Vaga
study [18], one patient had a clinical picture that
resembled HC, but the indometacin trial was not attempted
to confirm the diagnosis. This data suggests that the
prevalence of HC is possibly no more than 1 in 1838: in
effect, a rare condition.
A preponderance of women (5:1) initially was noted in
the first 18 cases reported by Bordini and colleagues [4].
However, the female preponderance has decreased with
more reported cases to 1.8:1 [5]. In a study of 34 patients,
the female-to-male ratio was 2.4:1 [7], and in the recent
study of 39 patients [16￿￿], there was a small female
preponderance (1.6:1), which is in line with the literature
and is less than is seen in patients with migraine.
Family History and Genetics
A family history of clear HC has not been reported in the
available literature. Pareja and colleagues [19] described a
patient with episodic HC who had a sister with HC, but
unfortunately, detailed information regarding the headache
was not reported. In 1999, a case report describing a
coincidental occurrence of familial hemiplegic migraine
and primary HC was suggested to be unlikely to be due to
chance because of a very low incidence of both headache
types, suggesting a common pathophysiological link [20].
Specific genetic studies have not been carried out in HC,
and the rarity of this disorder will make this difficult. In the
study of 39 patients with HC [16￿￿], the relationship
between the presence of migrainous biology was assessed
and it was found that migraine or headache not otherwise
specified was present in the family history of 61% of
patients. However, this data does not exclude the possibility
that some of the relatives could have HC because the trial
was not assessed due to the design of the study. Therefore,
future studies should focus on performing an indometacin
trial on the relatives of patients with HC who have a clinical
picture suggestive of HC.
Pathophysiology
The pathophysiology of HC is poorly understood. Craniovas-
cular involvement has been investigated with orbital phlebog-
raphy in six patients, but only in one patient was there an
abnormality consisting of bilateral narrowing of the ophthal-
mic veins, which may have been a nonspecific finding with
unilateralpain[21]. The pain pressure thresholds are reported
to be reduced in patients with HC [22], similar to cases of
paroxysmal hemicrania and cluster headache (CH) [23].
Pupillometric studies have shown no clear abnormality in
HC [24], and studies of facial sweating have shown modest
changes similar to those seen in PH [25].
An important development resulting in greater insight
into the pathophysiology of primary headache syndrome
comes from functional brain imaging that suggested a role
for subcortical neural structures [26]. A positron emission
tomography study in HC showed activation of the
contralateral posterior hypothalamus, with correlates with
hypothalamic activation in CH and the trigeminal auto-
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pons, ventrolateral midbrain (extending over the red
nucleus and substantia nigra), and pontomedullary junction
[27]. The ipsilateral dorsal pontine region is similar to that
seen in migraine [28–30]. These findings, together with the
clinical phenotype, suggest HC is unique and overlaps with
both TACs and migraine. The complete response to
indometacin may be due in part to the activation of the
ventral midbrain, red nucleus, and substantia nigra, which
is active during the painful exacerbation of HC and inactive
after indometacin administration. It is interesting that TACs
and HC show activation of posterior hypothalamus and
prominent cranial autonomic features are present in
association with headache.
It has been suggested the cranial autonomic features may
be prominent in these syndromes owing to central disinhi-
bition of the trigeminal-autonomic reflex by the hypothal-
amus [31]. Indeed, there are direct hypothalamic–trigeminal
connections [32], and the hypothalamus is known to have a
modulatory role on the nociceptive pathways [33]. The
activation of the region of the posterior hypothalamus
observed in the TACs and HC with neuroimaging studies
underlines an important role in the primary headache
syndromes for this region. Only further studies and detailed
anatomical work will allow us to understand the role of the
region more completely in HC and indeed, more broadly in
the TACs.
Clinical Features and Diagnosis
The current second edition of the ICHD [14] defines HC by
the presence of unilateral continuous daily headache
without side shift. The pain is considered to be moderate
in intensity, but there may be exacerbations of severe pain.
During exacerbations, there should be at least one ipsilat-
eral cranial autonomic symptom, such as conjunctival
injection, lacrimation, nasal blockage, rhinorrhea, ptosis,
or miosis. Cases of patients with side shift of pain have
been noted [16￿￿], suggesting the condition is not side
locked, and therefore, side shift of pain should not preclude
an indometacin trial. The cranial autonomic features do not
always occur with the exacerbation of the pain [7, 12￿,
16￿￿] and also, during a detailed interview, a wider range of
cranial autonomic features can be detected [16￿￿]. The
current IHS classification [14] describes the pain as
moderate in intensity with exacerbation of severe pain.
From a recent cohort [16￿￿], it emerged that severe pain is
reported in 70% of the patients, reinforcing the importance
of timely diagnosis.
In addition, it also has been suggested that unilateral
photophobia or phonophobia, or both, are more frequent in
HC and TACs such as CH, paroxysmal hemicrania, and
SUNCT (short-lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing) than in
migraine and NDPH [34]. In a cohort of 39 patients [16￿￿],
79% had phonophobia, which was unilateral in 48%, and
74% had photophobia, which was unilateral in 48%. The
presence of these unilateral symptoms may be clinically
useful pointers; however, further comparison studies be-
tween HC and unilateral chronic migraine are needed to
confirm the clinical importance of these data.
It also has emerged that more than half of the patients
show signs of agitation or restlessness or both, but also,
more than half of the patients have sensitivity to movement.
This is useful information because it once again suggests
that this condition shares some part of the TAC and
migraine phenotypes, which is consistent with the func-
tional imaging data. In the future, studies that correlate
imaging and phenotype may further elucidate the basis of
the symptoms our patients report.
Current criteria [14] for the diagnosis of HC mandate
daily and continuous pain without pain-free periods for
more than 3 months. Typically, HC is a chronic condition
with the episodic form occurring less often. The current
classification [14] does not include criteria that indicate
how to classify the chronic and episodic forms based on
duration and frequency of the pain. Recent data [16￿￿]
confirm that chronic HC can arise de novo (primary chronic
HC), or evolve from the episodic subtype (secondary HC).
In addition, episodic HC can arise de novo (primary
episodic form), or some patients can switch from chronic
to episodic form (secondary episodic). Most of the patients
described in this cohort had the primary chronic form,
which is in line with the current literature [7]. At present,
there is not a clear classification for these two subforms,
and the authors suggested the following possible classifi-
cation: the term chronic should apply to patients without
pain-free periods for at least 1 year, and the term episodic
should apply to patients who have pain-free periods of at
least 1 day.
Differential Diagnosis of Hemicrania Continua
The differential diagnosis of long-lasting unilateral head-
ache includes HC, unilateral chronic migraine, NDPH
(probably largely its migrainous subtype) [35], and the
other TACs when they occur with background pain, notably
paroxysmal hemicrania. HC can be differentiated from
chronic migraine and NDPH by the positive response to
indometacin [35]. The differential diagnosis between HC
and paroxysmal hemicrania with interictal pain can be
difficult, and certainly, a headache diary is very useful
during the workup of HC. In our experience, HC typically
has less prominent cranial autonomic features than parox-
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is typically more severe than the interictal pain in
paroxysmal hemicrania. In addition, painful exacerbations
in HC are long lasting, usually several hours, and less
frequent, whereas those in paroxysmal hemicrania are short
lasting, typically a few minutes to 1 h, and occur many
times a day. In general, a careful history supplemented with
a headache diary allows these two headache types to be
dissected one from another (Table 1).
Diagnosis and Investigations
The diagnosis is made on the basis of clinical history,
neurological examination, and a therapeutic trial with indo-
metacin. The indometacin test can be performed in two
different ways: by making use of an oral trial or a placebo-
controlled Indotest test [16]. The mean daily dosage in one
cohort was 137 mg with a range of 25–225 mg [7]. In
another cohort of 39 patients with HC [16], all patients
(81%) who could tolerate oral indometacin had an absolute
response to the oral trial. The range of effective daily doses
in our cohort varied between 50 mg to 500 mg per day.
Some three quarters of patients reported side effects at some
point, whereas only about a quarter of patients reported side
effects during the placebo-controlled Indotest. The latter
consists of parenteral single-blind administration of indome-
tacin, 100 or 200 mg, or placebo. The authors suggest the
placebo-controlled indometacin test may be the gold stan-
dard when applied, facilitating diagnosis and research. An
important question [12￿] that has emerged and has not been
addressed yet is whether medication overuse, in particular
opioids, can influence the response to indometacin [36].
Medication overuse also has been reported in patients with
HC [16￿￿, 37] and in our practice, we prefer to stop
medication overuse, where it is possible, based on the
knowledge that medication can alter the clinical picture [38].
Nevertheless, we performed indometacin trials in both
contexts with positive and negative outcome. However, in
our original study [16￿￿], we did not specifically address this
question. Future clinical and animal studies are needed to
advance the knowledge in this specific field.
Table 1 Comparison based on the cohorts of patients with trigeminal autonomic cephalalgia and hemicrania continua
Headache characteristics Cluster headache[44] Paroxysmal
hemicrania [45]
SUNCT/SUNA [46] Hemicrania continua [16]
Sex, M:F 3:1 1:1 1.5:1 1:1.6
Pain
￿ Quality Sharp/stabbing/
throbbing
Sharp/stabbing/
throbbing
Sharp/stabbing/
throbbing
Throbbing/sharp/constant
￿ Severity Very severe Very severe Severe Moderate/severe/very severe
￿ Distribution
a V1 >C2 > V2 > V3 V1 > C2 > V2 > V3 V1 > C2 > V2 > V3 V1 > C2 > V2 > V3
Attacks
￿ Frequency (per day) 1–8 11 100 No pattern
￿ Length, min 30–180 2–50 1–5 30 min–7 days Background pain
Triggers
￿ Alcohol + + + + – +
￿ Nitroglycerin + + + + – ++
￿ Cutaneous ––+++ –
Agitation/restlessness 90% 80% 65% 69%
Episodic vs chronic, E:C 90:10 35:65 10:90 18:82
Circadian/circannual periodicity Present Absent Absent Absent
Treatment effects
￿ Oxygen 70% No effect No effect No effect
￿ Sumatriptan, 6 mg 90% 20% < 10% No effect
￿ indometacin No effect 100% No effect 100%
Migraine features with attacks
￿ Nausea 50% 40% 25% 53%
￿ Photophobia/phonophobia 65% 65% 25% 80%
aC cervical, V trigeminal
SUNA short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms, SUNCT short-lasting unilateral neuralgiform
headache attacks with conjunctival injection and tearing
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clearly showed that it still is misdiagnosed. In fact, in a
cohort of 25 patients [39￿], not one had received the correct
diagnosis before attending the headache center. Interesting-
ly, 85% of the patients were assessed by a physician within
6 months of the onset of symptoms, but the mean latency of
diagnosis was 5 years, with the average number of
physicians seen before the headache was correctly diag-
nosed being 4.6±2.2 years. A prompt diagnosis would save
hospital resources and relieve the patients more quickly.
Treatment
There is no other drug that is consistently effective in HC.
The essential management problem arises when indometa-
cin produces peptide ulcer disease. Again, the
cyclooxygenase-2 inhibitors seemed to offer a way forward,
but are no longer recommended. Topiramate has been
reported to be useful in HC [40, 41] and this is born out in
practice. Similarly, greater occipital nerve injection with
lidocaine and methylprednisolone has been reported to be
helpful [42].
In 2008, Burns and colleagues [43￿￿] prospectively
described a cohort of six patients with HC that underwent
occipital nerve stimulation with a bion device. They found
that in a long-term follow-up, four of six patients reported a
substantial improvement (80%–90%), one patient reported
a 30% improvement, and one patient reported that his pain
was worse by 20%. The authors suggested the new
miniaturized device was safe and effective as it represents
a potential new option for the treatment of HC.
Conclusions
Since Sjaastad and Spierings [2] first coined the term in
1984, our knowledgeof HC has progressed considerably in
understanding both the pathophysiology and clinical pre-
sentation. It is a severe and disabling condition that
deserves a prompt diagnosis. Amendments to the current
criteria have been proposed based on the clinical data from
a substantial cohort [16￿￿]. The gold standard treatment is
indometacin, and occipital nerve stimulation may represent
a valid option in a selectgroup of patients. Future directions
also will include clinical studies that try to identify possible
markers that can help during the differential diagnosis
between HC and unilateral chronic migraine and studies
that evaluate whether medication overuse, specifically
opioids, can alter the response to indometacin. We suggest
that a placebo-controlled indometacin test should be
considered the gold standard when applied, facilitating
diagnosis and research. We also draw attention to the need
for more neurologists and general practitioners to have
headache training to reduce the number of patients who still
are misdiagnosed.
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